Ablynx N.v.

Merck Patent Gmbh

Argenx Bv

Argen-x N.v.

Argenx Bvba

Michael John Scott Saunders

Johannes Joseph Wilhelmus De Haard

Peter Vanlandschoot

Peter Verheesen

Christophe Blanchetot

Renee De Bruin

Edward Dolk

Hendricus Renerus Jacobus Mattheus Hoogenboom

Torsten Dreier

Karen Silence

Guy Hermans

Peter Ulrichts

Mahan Moshir

Harald Wajant

Sofie Maria Elvire Gabriels

Hans De Haard

Maria Gonzalez Pajuelo

Regorius Leurs

Martine Smit

Sven Jähnichen

Joost Alexander Kolkman

Olivier Leger

Yolande Chvatchko

Heidi Rommelaere

Ann Union

Alain Vicari

Amanda E I Proudfoot

Denis Bruniquel

Laurent Chevalet

Dominique Schols

Catelijne Stortelers

Erik Depla

Francis Descamps

Alexander Szyroki

Xavier Saelens

Philippe Van Rompaey

Anna Hultberg

Maarten Van Roy

Pascal Gerard Merchiers

Bert Schepens

Jose Melero

David Andre Baptiste Maussang-Detaille

Hendrik Adams

Bram Maassen

Cornelis Theodorus Verrips

Steven Van Gucht

Robert Anthony Weiss

Nigel J Temperton

Michael Marie Harmsen

Amanda EI Proudfoot

Nigel James Temperton

The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as 'APC target') or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Amino acid sequences that modulate the interaction between cells of the immune system

The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same

The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.

Antibodies to CD70

The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.

The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as 'APC target') or a target on a T-cell (also referred to herein as 'T-cell target'). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same

The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.

Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Amino acid sequences of the present invention may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

Amino acid sequences directed against cellular receptors for viruses and bacteria

The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders

Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

Growing community of inventors

Brussels, Belgium

Michael John Scott Saunders